Glucoryl-MV 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2 mg), Metformin (500 mg), and Voglibose (0.2 mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, resulting in reduced postprandial hyperglycemia. The sustained-release formulation ensures a gradual and prolonged release of the active ingredients, promoting better glycemic control with reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release formulations. Glucoryl-MV 2 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled by monotherapy or dual therapy. It should be used under medical supervision with regular monitoring of blood glucose and renal function. Caution is advised in patients with renal or hepatic impairment, and hypoglycemia risk should be considered, especially when combined with other antidiabetic agents.